ArticleInternational journal of clinical and experimental pathology2013
Cutaneous pseudolymphoma: a case report with an immunohistochemical study.
Article in International journal of clinical and experimental pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Rare Case Report of Periorbital Pseudolymphoma.Cureus · 2023Article
- Cutaneous pseudolymphoma: A clinicopathological study and immunohistochemical patterns.Caspian journal of internal medicine · 2021Article
- Hirudotherapy - a rare cause of pseudolymphoma.Postepy dermatologii i alergologii · 2018Article
- Perianal pseudolymphoma: A case report and review of the literature.International journal of surgery case reports · 2017Article
- Radiotherapy in aggressive cutaneous pseudolymphoma: a case report and review of literature.Radiation oncology journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous pseudolymphoma (C-PSL) is defined as reactive polyclonal benign lymphoproliferative process predominantly composed of either B-cells or T-cells, localized or disseminated. It heals spontaneously after cessation of the causative factor (e.g. drugs) or after non-aggressive treatment. The author herein presents a case of C-PSL with an immunohistochemical study. A 78-year-old man consulted our hospital because of slightly itching skin swelling on the arm. He denied insect bite and traumatic injury. His usual intake drugs were drugs of hypertension, hyperlipidemia, diabetes mellitus, and emotional disorders. Physical examination showed mildly erosive swelling of the am. The lesion measured 1 x 1 x 0.2 cm. Biopsy of the lesion was taken, and it revealed excessive proliferation of small lymphoid cells. The lymphoid cells lacked apparent atypical features and appeared matures. Lymphoblastic cells with nucleoli were scattered. Nodular structures were also seen in the lower dermis. Immunohistochemically, the lymphoid cells were positive for vimentin, CD3, CD4, CD5, CD8, CD10, CD15, CD20, CD23, CD30, CD43, CD38, CD138, CD45RO, CD79α, bcl-2, bcl-6, κ-chain, λ-chain, and Ki-67 (labeling index=7%). No light chain restriction is seen. The lymphoblastic cells were positively labeled for CD15 and CD30. Plasma cells positive for CD38, CK79α and CD138 were seen in a significant amounts. They were negative for cytokeratin (CK) CAM5.2, CKAE1/3, CK34BE12, CK5/6, CK7, CK8, CK18, CK19, CK20, EMA, CEA, CD56, CD57, p53, KIT, PDGFRA, and cyclin D1. Because the constituent cells were both B-cells including plasm cells and T-cells, no light-chain restriction was seen, and no histological atypia was seen, a diagnosis of cutaneous pseudolymphoma was made. The low Ki-67 labeling and negative p53 also suggested the diagnosis. The lesion slightly reduced in size (from 1 cm to 0.7 cm), the causative agent was still unknown 11 months after the biopsy.
Indexed as
Identifiers
23638232PMC3638111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.